NCT00486876

Brief Summary

The primary objectives of this study are to evaluate the clinical safety and tolerability and to assess the efficacy of 100 mg, 200 mg, and 300 mg BID dextofisopam compared with placebo in female outpatients with diarrhea-predominant or alternating irritable bowel syndrome (IBS).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
324

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Jun 2007

Geographic Reach
1 country

79 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2007

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

June 13, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 15, 2007

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2009

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2009

Completed
Last Updated

August 2, 2011

Status Verified

August 1, 2011

Enrollment Period

2.3 years

First QC Date

June 13, 2007

Last Update Submit

August 1, 2011

Conditions

Keywords

Irritable bowel syndromeDiarrhea predominant Irritable Bowel SyndromeAlternating Irritable Bowel Syndrome

Outcome Measures

Primary Outcomes (1)

  • The percentage of weeks for which patients record adequate overall relief of IBS symptoms during the double blind period (12 weeks of treatment).

    June 07 thru August 09

Study Arms (4)

1

PLACEBO COMPARATOR

Placebo

Drug: Dextofisopam

2

EXPERIMENTAL

100 mg BID

Drug: Dextofisopam

3

EXPERIMENTAL

200 mg BID

Drug: Dextofisopam

4

EXPERIMENTAL

300 mg BID

Drug: Dextofisopam

Interventions

capsules, 0 (placebo), 100, 200, and 300 mg BID for 12 weeks

1234

Eligibility Criteria

Age18 Years - 65 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \. Outpatient post-menopausal or no pregnant females,18 to 65 years old
  • \. Irritable bowel syndrome, which meet the Rome III criteria for IBS of the diarrhea-predominant or the alternating subtype
  • \. Able to give informed consent
  • Willingness to make daily calls on a touch-tone telephone

You may not qualify if:

  • \. Clinically significant abnormality on the screening tests.
  • \. Use of any other investigational drug within 30 days before screening visit.
  • \. Serious underlying diseases, including psychiatric disorders or current history of conditions affecting bowel habits
  • \. Previous treatment with tofisopam Related drugs.
  • \. History or presence of clinically significant medical disease that might compromise the study or be detrimental to the patient, such as
  • \. Subject has exclusively constipation-predominant IBS.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (79)

Alliance Clinical Research

Birmingham, Alabama, 35215, United States

Location

Clinical Research Associates

Huntsville, Alabama, 35801, United States

Location

Mobile Medical and Diagnostic Center

Mobile, Alabama, 36617, United States

Location

Radiant Research, Phoenix Southwest

Chandler, Arizona, 85225, United States

Location

Mayo Clinic Arizona

Scottsdale, Arizona, 85259, United States

Location

Arkansas Gastroenterology

Sherwood, Arkansas, 72120, United States

Location

Providence Clinical Research

Burbank, California, 91505, United States

Location

Discovery Clinical Research

Encinitas, California, 92024, United States

Location

Digestive and Liver Disease Specialists

Garden Grove, California, 92840, United States

Location

Community Clinical Trials

Orange, California, 92868, United States

Location

Advance Clinical Research Institute

Orange, California, 92869, United States

Location

Northern California Research

Sacramento, California, 95831, United States

Location

Medical Associates Research Group

San Diego, California, 92123, United States

Location

Westlake Medical Research

Westlake Village, California, 91361, United States

Location

Lynn Institute of the Rockies

Colorado Springs, Colorado, 80909, United States

Location

Rx Clinical Trials

Washington D.C., District of Columbia, 20010, United States

Location

Meridien Research

Brooksville, Florida, 34613, United States

Location

Borland-Groover Clinic

Jacksonville, Florida, 32256, United States

Location

Genesis Research International

Longwood, Florida, 32779, United States

Location

Well Pharma Medical Research, Corp.

Miami, Florida, 33143, United States

Location

Renstar Medical Research

Ocala, Florida, 34471, United States

Location

Compass Research, LLC

Orlando, Florida, 32806, United States

Location

The Clinical Research Center of Northwest Florida

Panama City, Florida, 32405, United States

Location

ACCORD Clinical Research, LLC

Port Orange, Florida, 32129, United States

Location

Meridien Research

St. Petersburg, Florida, 33709, United States

Location

Palm Beach Research Center

West Palm Beach, Florida, 33409, United States

Location

Mount Vernon Clinical Research

Atlanta, Georgia, 30328, United States

Location

Perimeter Institute for Clinical Research, Inc. (PICR)

Atlanta, Georgia, 30338, United States

Location

North Georgia Clinical Research

Woodstock, Georgia, 30189, United States

Location

Rosemark Women Care Specialists

Idaho Falls, Idaho, 83404, United States

Location

Rockford Gastroenterology Associates

Rockford, Illinois, 61101, United States

Location

Heartland Research Associates, LLC

Arkansas City, Kansas, 67005, United States

Location

Heartland Research Associates

Wichita, Kansas, 67207, United States

Location

Trover Health System

Madisonville, Kentucky, 42431, United States

Location

Clinical Trials of America

Shreveport, Louisiana, 71101, United States

Location

Maryland Digestive Disease Research, LLC

Laurel, Maryland, 20707, United States

Location

Capital Gastroenterology Consultants, PA

Silver Spring, Maryland, 20901, United States

Location

University of Michigan

Ann Arbor, Michigan, 48109, United States

Location

Gastrointestinal Associates

Jackson, Mississippi, 39202, United States

Location

Meridan Clinical Research

Omaha, Nebraska, 68134, United States

Location

Digestive Disease Specialists

Las Vegas, Nevada, 89128, United States

Location

New Mexico Clinical Research & Osteoporosis Center, Inc

Albuquerque, New Mexico, 87106, United States

Location

Long Island Clinical Research Associates

Great Neck, New York, 11021, United States

Location

Long Island Gastrointestinal Research Group

Great Neck, New York, 11023, United States

Location

Winthrop University Hospital

Mineola, New York, 11501, United States

Location

The Weill Medical College Of Cornell University

New York, New York, 10021, United States

Location

Asheville Gastroenterology Associates

Asheville, North Carolina, 28801, United States

Location

Cumberland Research Associates, LLC.

Fayetteville, North Carolina, 28304, United States

Location

Clinical Trials of America, Inc.

Hickory, North Carolina, 28601, United States

Location

Clinical Trials of America

Winston-Salem, North Carolina, 27103, United States

Location

Medical Frontiers, LLC

Carlisle, Ohio, 45005, United States

Location

Consultants for Clinical Research

Cincinnati, Ohio, 45219, United States

Location

Digestive Health Network

Cincinnati, Ohio, 45220, United States

Location

Gastroenterology Research Consultants of Greater Cincinnati

Cincinnati, Ohio, 45242, United States

Location

Rapid Medical Research, Inc.

Cleveland, Ohio, 44122, United States

Location

Gastrointestinal & Liver Diseases Consultants, PC

Dayton, Ohio, 45440, United States

Location

Toledo Center for Clinical Research

Sylvania, Ohio, 43560, United States

Location

Family Practice Center of Wadsworth, Inc.

Wadsworth, Ohio, 44281, United States

Location

Lynn Institute of Norman

Norman, Oklahoma, 73069, United States

Location

Lynn Health Science Institute

Oklahoma City, Oklahoma, 73112, United States

Location

Aquilo Research

Yukon, Oklahoma, 73099, United States

Location

TriValley Primary Care-Pennridge

Perkasie, Pennsylvania, 18944, United States

Location

Coastal Carolina Research Center

Mt. Pleasant, South Carolina, 29464, United States

Location

TriCities Medical Research

Bristol, Tennessee, 37620, United States

Location

ClinSearch

Chattanooga, Tennessee, 37421, United States

Location

Memphis Gastroenterology Group

Germantown, Tennessee, 38138, United States

Location

Gastroenterology Associates

Kingsport, Tennessee, 37660, United States

Location

Austin Gastroenterology, PA

Austin, Texas, 78745, United States

Location

Radiant Research of Dallas-North

Dallas, Texas, 75231, United States

Location

Research Across America

Dallas, Texas, 75234, United States

Location

Sun Research Institute

San Antonio, Texas, 78205, United States

Location

Quality Research, Inc.

San Antonio, Texas, 78209, United States

Location

Gastroenterology Clinic of San Antonio

San Antonio, Texas, 78229, United States

Location

Advanced Research Institute

Ogden, Utah, 84405, United States

Location

Gastroenterology Associates of Tidewater

Chesapeake, Virginia, 23320, United States

Location

Professional Place Medical Group, LLC

Chesapeake, Virginia, 23320, United States

Location

New River Valley Research Institute

Christiansburg, Virginia, 24073, United States

Location

National Clinical Recruiters, Inc

Richmond, Virginia, 23294, United States

Location

Wenatchee Valley Medical Center

Wenatchee, Washington, 98801, United States

Location

MeSH Terms

Conditions

Irritable Bowel Syndrome

Interventions

tofisopam

Condition Hierarchy (Ancestors)

Colonic Diseases, FunctionalColonic DiseasesIntestinal DiseasesGastrointestinal DiseasesDigestive System Diseases

Study Officials

  • S Colin Neill

    President and CFO, Pharmos

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

June 13, 2007

First Posted

June 15, 2007

Study Start

June 1, 2007

Primary Completion

September 1, 2009

Study Completion

October 1, 2009

Last Updated

August 2, 2011

Record last verified: 2011-08

Locations